NCT02360579 2026-03-25
LN-144
Iovance Biotherapeutics, Inc.
Phase 2 Completed
Clinical Trials
5 trialsNCT07288203 2026-01-12
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
Iovance Biotherapeutics, Inc.
Phase 2 Recruiting
NCT06481592 2025-10-30
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
Iovance Biotherapeutics, Inc.
Phase 2 Recruiting
NCT03645928 2025-06-19
LN-144
Iovance Biotherapeutics, Inc.
Phase 2 Recruiting
NCT06151847 2024-02-28
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
University of Kansas Medical Center
Phase 2 Unknown